1-5 of 5
Cathy Burton
Close
Sort by
Journal Articles

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma

Findlay Bewicke-Copley, Koorosh Korfi, Shamzah Araf, Brendan Hodkinson, Emil Kumar, Thomas Cummin, Margaret Ashton-Key, Sharon Barrans, Suzan van Hoppe, Cathy Burton, Mohamed Elshiekh, Simon Rule, Nicola Crosbie, Andrew Clear, Maria Calaminici, Hendrik Runge, Robert K. Hills, David W. Scott, Lisa M. Rimsza, Geetha Menon, Chulin Sha, John R. Davies, Ai Nagano, Andrew Davies, Daniel Painter, Alexandra Smith, John Gribben, Kikkeri N. Naresh, David R. Westhead, Jessica Okosun, Andrew Steele, Daniel J. Hodson, Sriram Balasubramanian, Peter Johnson, Jun Wang, Jude Fitzgibbon
Journal: Blood Advances
Blood Adv (2023) 7 (5): 845–855.
https://doi.org/10.1182/bloodadvances.2022007536
Published: 2023
Includes: Supplemental data
Journal Articles

Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network

Simon Crouch, Daniel Painter, Sharon L. Barrans, Eve Roman, Philip A. Beer, Susanna L. Cooke, Paul Glover, Suzan J.L. Van Hoppe, Nichola Webster, Stuart E. Lacy, Camilo Ruiz, Peter J. Campbell, Daniel J. Hodson, Russell Patmore, Cathy Burton, Alexandra Smith, Reuben M. Tooze
Journal: Blood Advances
Blood Adv (2022) 6 (21): 5716–5731.
https://doi.org/10.1182/bloodadvances.2021005284
Published: 2022
Includes: Supplemental data
Journal Articles

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Clinical Trials & Observations
Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew J. Davies, Dima El-Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah, Ying Ying Peng, Iman Qureshi, Juanah Addada, Rocio Figueroa Mora, Neil Phillips, Andrea Kuhnl, Elizabeth Davies, David Wrench, Pamela McKay, Indrani Karpha, Anna Cowley, Richard Karim, Sarah Challenor, Vikram Singh, Cathy Burton, Rebecca Auer, Chris Williams, Joel Cunningham, Angus Broom, Anita Arasaretnam, Claire Roddie, Tobias Menne, William Townsend
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2920–2926.
https://doi.org/10.1182/bloodadvances.2021005953
Published: 2022
Includes: Supplemental data
Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Clinical Trials & Observations
Jonathan C. Strefford, Malgorzata Nowicka, Chantal E. Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V. Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N. Potter, Matthew J. J. Rose-Zerilli, Laurie H. Sehn, Marek Trněný, Umberto Vitolo, Christopher R. Bolen, Christian Klein, Andrea Knapp, Mikkel Z. Oestergaard, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2935–2944.
https://doi.org/10.1182/bloodadvances.2020003985
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Clinical Trials & Observations
Malgorzata Nowicka, Laura K. Hilton, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter, Stephen A. Beers, Kathleen N. Potter, Christopher R. Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W. Scott, Laurie H. Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K. Rushton, Graham W. Slack, Pedro Farinha, Jonathan C. Strefford, Mikkel Z. Oestergaard, Ryan D. Morin, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2945–2957.
https://doi.org/10.1182/bloodadvances.2021004770
Published: 2021
Includes: Supplemental data